INVEX THERAPEUTICS LTD - Announcements

Market Cap $6.012M Add to my watchlist

Healthcare

Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical... Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Our primary focus is on the orphan disease Idiopathic Intracranial Hypertension (IIH), a large and growing market opportunity with no regulatory cleared treatmentsMore

Announcements

Filter Results

All Price Sensitive Only

IXC	Details of Auditor Appointment/Resignation		19/04/24	176.2KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	12/04/24	480.45KB	Share
IXC	Change of Director's Interest Notice		09/04/24	218.02KB	Share
IXC	Notification of cessation of securities - IXC		08/04/24	12.68KB	Share
IXC	Change of Director's Interest Notice		03/04/24	219.69KB	Share
IXC	Amendment to Appendix 3A.4		22/03/24	170.57KB	Share
IXC	ATO Class Ruling Return of Capital	PRICE SENSITIVE	20/03/24	349.06KB	Share
IXC	Update on R&D Tax Rebate from UK Government		05/03/24	184.22KB	Share
IXC	Appendix 4D and Half year report	PRICE SENSITIVE	16/02/24	544.81KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	11/01/24	460KB	Share
IXC	Notification of cessation of securities - IXC		29/12/23	21.56KB	Share
IXC	Invex and Peptron Mutually Terminate Manufacturing Agreement	PRICE SENSITIVE	22/12/23	180.45KB	Share
IXC	Effective Date of Capital Return		05/12/23	182.26KB	Share
IXC	Results of Meeting		05/12/23	197.78KB	Share
IXC	Payment of Capital Return Proceeds		30/11/23	345.92KB	Share
IXC	Results of Meeting		28/11/23	195.14KB	Share
IXC	Chair's Address to Shareholders		28/11/23	214.91KB	Share
IXC	Change in substantial holding		28/11/23	153.34KB	Share
IXC	Change of Director's Interest Notice x 3		27/11/23	290.07KB	Share
IXC	Notification of cessation of securities - IXC		22/11/23	21.49KB	Share
IXC	Invex Granted European Patent for Exenatide in Hydrocephalus	PRICE SENSITIVE	22/11/23	209.03KB	Share
IXC	Notification of cessation of securities - IXC		20/11/23	21.53KB	Share
IXC	Notification of cessation of securities - IXC		10/11/23	21.5KB	Share
IXC	Notification of cessation of securities - IXC		10/11/23	21.61KB	Share
IXC	Initial Director's Interest Notice		09/11/23	227.2KB	Share
IXC	Appointment of Non-executive Director		08/11/23	181.58KB	Share
IXC	Change in substantial holding		08/11/23	153.42KB	Share
IXC	Notice of General Meeting/Proxy Form		02/11/23	1.42MB	Share
IXC	Return of Capital - IXC		01/11/23	22.66KB	Share
IXC	Proposed Capital Return to Shareholders of $14.0 Million	PRICE SENSITIVE	01/11/23	189.67KB	Share
IXC	Notification of cessation of securities - IXC		20/10/23	21.55KB	Share
IXC	Notice of Annual General Meeting/Proxy Form		19/10/23	1.44MB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	12/10/23	440.19KB	Share
IXC	Change in substantial holding		28/09/23	153.42KB	Share
IXC	Date of AGM and Closing Date for Director Nominations		25/09/23	172.73KB	Share
IXC	Becoming a substantial holder		31/08/23	103.83KB	Share
IXC	Change of Director's Interest Notice		25/08/23	252.3KB	Share
IXC	Invex issued US patent for Traumatic Brain Injury	PRICE SENSITIVE	23/08/23	207.93KB	Share
IXC	Invex to close IIH Evolve Phase III Clinical Trial	PRICE SENSITIVE	21/08/23	217.85KB	Share
IXC	Trading Halt	PRICE SENSITIVE	18/08/23	218.31KB	Share
IXC	Corporate Governance Statement 2023		17/08/23	390.78KB	Share
IXC	Appendix 4G		17/08/23	323.02KB	Share
IXC	Appendix 4E and Annual Report to shareholders	PRICE SENSITIVE	17/08/23	1.1MB	Share
IXC	Final Director's Interest Notice (AS)		10/07/23	248.7KB	Share
IXC	Final Director's Interest Notice		10/07/23	247.52KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	10/07/23	432.64KB	Share
IXC	Director Resignations and Appointment of Non-Executive Chair		03/07/23	184.23KB	Share
IXC	Phase III Clinical Trial Update and New IIH Market Analysis	PRICE SENSITIVE	28/06/23	297.29KB	Share
IXC	Invex Granted European Orphan Drug Designation for TBI	PRICE SENSITIVE	23/06/23	190.65KB	Share
IXC	Invex Receives Regulatory Approval for IIH EVOLVE in France	PRICE SENSITIVE	21/04/23	197.22KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	20/04/23	428.6KB	Share
IXC	Israel Ministry of Health Approval for IIH EVOLVE	PRICE SENSITIVE	20/04/23	195.97KB	Share
IXC	March Appendix 4C and Investor Conference Call Details		17/04/23	190.39KB	Share
IXC	Notification of cessation of securities - IXC		12/04/23	21.56KB	Share
IXC	German Approval for IIH EVOLVE Phase 3 Clinical Trial	PRICE SENSITIVE	20/03/23	195.69KB	Share
IXC	Publication of Invex IIH Phase II Pressure Trial Results		14/03/23	227.9KB	Share
IXC	Half Year Accounts	PRICE SENSITIVE	17/02/23	404.06KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/01/23	451.58KB	Share
IXC	Notification of cessation of securities - IXC		23/01/23	21.59KB	Share
IXC	Notice of Quarterly Investor Call		19/01/23	192.02KB	Share
IXC	First US Clinical Site Activated in IIH EVOLVE Phase III	PRICE SENSITIVE	19/01/23	198.37KB	Share
IXC	Invex Receives Approval for Paediatric Plan from the EMA	PRICE SENSITIVE	14/12/22	198.56KB	Share
IXC	Update - Notification regarding unquoted securities - IXC		08/12/22	28.25KB	Share
IXC	Change of Director's Interest Notice x 4		07/12/22	488.63KB	Share
IXC	Notification regarding unquoted securities - IXC		05/12/22	28.83KB	Share
IXC	Invex to Present at the MST Financial Biotech Forum		30/11/22	908.83KB	Share
IXC	MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ	PRICE SENSITIVE	25/11/22	193.89KB	Share
IXC	Investor Presentation		22/11/22	1.17MB	Share
IXC	Results of Meeting		22/11/22	150.21KB	Share
IXC	AGM Presentation		22/11/22	690.84KB	Share
IXC	AGM Chairmans Address		22/11/22	215.39KB	Share
IXC	First Patient Randomised in IIH EVOLVE Phase III Trial	PRICE SENSITIVE	21/11/22	205.06KB	Share
IXC	Invex Receives $0.46 Million R&D Tax Rebate	PRICE SENSITIVE	01/11/22	191.88KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/22	436.09KB	Share
IXC	Upcoming Presentation at Argonaut Biotech Briefing		26/10/22	936.35KB	Share
IXC	September Appendix 4C and Investor Conference Call Details		24/10/22	149.37KB	Share
IXC	First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial	PRICE SENSITIVE	24/10/22	195.69KB	Share
IXC	First Australian Site Activated in IIH EVOLVE Phase 3	PRICE SENSITIVE	24/10/22	192.5KB	Share
IXC	Notice of Annual General Meeting/Proxy Form		21/10/22	2.11MB	Share
IXC	Second HREC Approval for IIH EVOLVE Phase III Clinical Trial	PRICE SENSITIVE	30/09/22	206.16KB	Share
IXC	Date of AGM and Director Nominations		23/09/22	188.32KB	Share
IXC	Invex to Present at Virtual ASX Small and Mid-Cap Conference		12/09/22	1022.66KB	Share
IXC	Appendix 4G		19/08/22	319.56KB	Share
IXC	Corporate Governance Statement		19/08/22	386.99KB	Share
IXC	4E and Annual Report to shareholders	PRICE SENSITIVE	19/08/22	7.16MB	Share
IXC	Invex receives IND approval	PRICE SENSITIVE	19/08/22	212.82KB	Share
IXC	Trading Halt	PRICE SENSITIVE	18/08/22	212.3KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	06/07/22	454.29KB	Share
IXC	HREC and TGA Approval to Commence Phase 3 in Australia	PRICE SENSITIVE	04/07/22	207.47KB	Share
IXC	Appendix 4C and Investor Conference Call Details		01/07/22	190.21KB	Share
IXC	Invex Receives UK Approval to Commence Phase III Trial	PRICE SENSITIVE	29/06/22	201.44KB	Share
IXC	Upcoming Presentations to the 15th EUNOS Meeting		20/06/22	228.83KB	Share
IXC	Invex to Present at Aerospace Medical Association Meeting		20/05/22	232.1KB	Share
IXC	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	19/04/22	480.95KB	Share
IXC	March Appendix 4C and Investor Conference Call Details		13/04/22	189.38KB	Share
IXC	Executive Director Agreement		01/04/22	181.9KB	Share
IXC	Invex to Present at Upcoming Tech Biotech Broker Briefing		22/03/22	180.66KB	Share
IXC	Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/22	1.02MB	Share
IXC	Upcoming Presentations at 48th Annual NANOS Meeting		10/02/22	228.5KB	Share
IXC	New Executive Director and Chairman Agreements	PRICE SENSITIVE	31/01/22	200.14KB	Share

IXC Details of Auditor Appointment/Resignation
19/04/24		176.2KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
12/04/24	PRICE SENSITIVE	480.45KB	Share
IXC Change of Director's Interest Notice
09/04/24		218.02KB	Share
IXC Notification of cessation of securities - IXC
08/04/24		12.68KB	Share
IXC Change of Director's Interest Notice
03/04/24		219.69KB	Share
IXC Amendment to Appendix 3A.4
22/03/24		170.57KB	Share
IXC ATO Class Ruling Return of Capital
20/03/24	PRICE SENSITIVE	349.06KB	Share
IXC Update on R&D Tax Rebate from UK Government
05/03/24		184.22KB	Share
IXC Appendix 4D and Half year report
16/02/24	PRICE SENSITIVE	544.81KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
11/01/24	PRICE SENSITIVE	460KB	Share
IXC Notification of cessation of securities - IXC
29/12/23		21.56KB	Share
IXC Invex and Peptron Mutually Terminate Manufacturing Agreement
22/12/23	PRICE SENSITIVE	180.45KB	Share
IXC Effective Date of Capital Return
05/12/23		182.26KB	Share
IXC Results of Meeting
05/12/23		197.78KB	Share
IXC Payment of Capital Return Proceeds
30/11/23		345.92KB	Share
IXC Results of Meeting
28/11/23		195.14KB	Share
IXC Chair's Address to Shareholders
28/11/23		214.91KB	Share
IXC Change in substantial holding
28/11/23		153.34KB	Share
IXC Change of Director's Interest Notice x 3
27/11/23		290.07KB	Share
IXC Notification of cessation of securities - IXC
22/11/23		21.49KB	Share
IXC Invex Granted European Patent for Exenatide in Hydrocephalus
22/11/23	PRICE SENSITIVE	209.03KB	Share
IXC Notification of cessation of securities - IXC
20/11/23		21.53KB	Share
IXC Notification of cessation of securities - IXC
10/11/23		21.5KB	Share
IXC Notification of cessation of securities - IXC
10/11/23		21.61KB	Share
IXC Initial Director's Interest Notice
09/11/23		227.2KB	Share
IXC Appointment of Non-executive Director
08/11/23		181.58KB	Share
IXC Change in substantial holding
08/11/23		153.42KB	Share
IXC Notice of General Meeting/Proxy Form
02/11/23		1.42MB	Share
IXC Return of Capital - IXC
01/11/23		22.66KB	Share
IXC Proposed Capital Return to Shareholders of $14.0 Million
01/11/23	PRICE SENSITIVE	189.67KB	Share
IXC Notification of cessation of securities - IXC
20/10/23		21.55KB	Share
IXC Notice of Annual General Meeting/Proxy Form
19/10/23		1.44MB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
12/10/23	PRICE SENSITIVE	440.19KB	Share
IXC Change in substantial holding
28/09/23		153.42KB	Share
IXC Date of AGM and Closing Date for Director Nominations
25/09/23		172.73KB	Share
IXC Becoming a substantial holder
31/08/23		103.83KB	Share
IXC Change of Director's Interest Notice
25/08/23		252.3KB	Share
IXC Invex issued US patent for Traumatic Brain Injury
23/08/23	PRICE SENSITIVE	207.93KB	Share
IXC Invex to close IIH Evolve Phase III Clinical Trial
21/08/23	PRICE SENSITIVE	217.85KB	Share
IXC Trading Halt
18/08/23	PRICE SENSITIVE	218.31KB	Share
IXC Corporate Governance Statement 2023
17/08/23		390.78KB	Share
IXC Appendix 4G
17/08/23		323.02KB	Share
IXC Appendix 4E and Annual Report to shareholders
17/08/23	PRICE SENSITIVE	1.1MB	Share
IXC Final Director's Interest Notice (AS)
10/07/23		248.7KB	Share
IXC Final Director's Interest Notice
10/07/23		247.52KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
10/07/23	PRICE SENSITIVE	432.64KB	Share
IXC Director Resignations and Appointment of Non-Executive Chair
03/07/23		184.23KB	Share
IXC Phase III Clinical Trial Update and New IIH Market Analysis
28/06/23	PRICE SENSITIVE	297.29KB	Share
IXC Invex Granted European Orphan Drug Designation for TBI
23/06/23	PRICE SENSITIVE	190.65KB	Share
IXC Invex Receives Regulatory Approval for IIH EVOLVE in France
21/04/23	PRICE SENSITIVE	197.22KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
20/04/23	PRICE SENSITIVE	428.6KB	Share
IXC Israel Ministry of Health Approval for IIH EVOLVE
20/04/23	PRICE SENSITIVE	195.97KB	Share
IXC March Appendix 4C and Investor Conference Call Details
17/04/23		190.39KB	Share
IXC Notification of cessation of securities - IXC
12/04/23		21.56KB	Share
IXC German Approval for IIH EVOLVE Phase 3 Clinical Trial
20/03/23	PRICE SENSITIVE	195.69KB	Share
IXC Publication of Invex IIH Phase II Pressure Trial Results
14/03/23		227.9KB	Share
IXC Half Year Accounts
17/02/23	PRICE SENSITIVE	404.06KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
25/01/23	PRICE SENSITIVE	451.58KB	Share
IXC Notification of cessation of securities - IXC
23/01/23		21.59KB	Share
IXC Notice of Quarterly Investor Call
19/01/23		192.02KB	Share
IXC First US Clinical Site Activated in IIH EVOLVE Phase III
19/01/23	PRICE SENSITIVE	198.37KB	Share
IXC Invex Receives Approval for Paediatric Plan from the EMA
14/12/22	PRICE SENSITIVE	198.56KB	Share
IXC Update - Notification regarding unquoted securities - IXC
08/12/22		28.25KB	Share
IXC Change of Director's Interest Notice x 4
07/12/22		488.63KB	Share
IXC Notification regarding unquoted securities - IXC
05/12/22		28.83KB	Share
IXC Invex to Present at the MST Financial Biotech Forum
30/11/22		908.83KB	Share
IXC MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ
25/11/22	PRICE SENSITIVE	193.89KB	Share
IXC Investor Presentation
22/11/22		1.17MB	Share
IXC Results of Meeting
22/11/22		150.21KB	Share
IXC AGM Presentation
22/11/22		690.84KB	Share
IXC AGM Chairmans Address
22/11/22		215.39KB	Share
IXC First Patient Randomised in IIH EVOLVE Phase III Trial
21/11/22	PRICE SENSITIVE	205.06KB	Share
IXC Invex Receives $0.46 Million R&D Tax Rebate
01/11/22	PRICE SENSITIVE	191.88KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
27/10/22	PRICE SENSITIVE	436.09KB	Share
IXC Upcoming Presentation at Argonaut Biotech Briefing
26/10/22		936.35KB	Share
IXC September Appendix 4C and Investor Conference Call Details
24/10/22		149.37KB	Share
IXC First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial
24/10/22	PRICE SENSITIVE	195.69KB	Share
IXC First Australian Site Activated in IIH EVOLVE Phase 3
24/10/22	PRICE SENSITIVE	192.5KB	Share
IXC Notice of Annual General Meeting/Proxy Form
21/10/22		2.11MB	Share
IXC Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
30/09/22	PRICE SENSITIVE	206.16KB	Share
IXC Date of AGM and Director Nominations
23/09/22		188.32KB	Share
IXC Invex to Present at Virtual ASX Small and Mid-Cap Conference
12/09/22		1022.66KB	Share
IXC Appendix 4G
19/08/22		319.56KB	Share
IXC Corporate Governance Statement
19/08/22		386.99KB	Share
IXC 4E and Annual Report to shareholders
19/08/22	PRICE SENSITIVE	7.16MB	Share
IXC Invex receives IND approval
19/08/22	PRICE SENSITIVE	212.82KB	Share
IXC Trading Halt
18/08/22	PRICE SENSITIVE	212.3KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
06/07/22	PRICE SENSITIVE	454.29KB	Share
IXC HREC and TGA Approval to Commence Phase 3 in Australia
04/07/22	PRICE SENSITIVE	207.47KB	Share
IXC Appendix 4C and Investor Conference Call Details
01/07/22		190.21KB	Share
IXC Invex Receives UK Approval to Commence Phase III Trial
29/06/22	PRICE SENSITIVE	201.44KB	Share
IXC Upcoming Presentations to the 15th EUNOS Meeting
20/06/22		228.83KB	Share
IXC Invex to Present at Aerospace Medical Association Meeting
20/05/22		232.1KB	Share
IXC Quarterly Activities/Appendix 4C Cash Flow Report
19/04/22	PRICE SENSITIVE	480.95KB	Share
IXC March Appendix 4C and Investor Conference Call Details
13/04/22		189.38KB	Share
IXC Executive Director Agreement
01/04/22		181.9KB	Share
IXC Invex to Present at Upcoming Tech Biotech Broker Briefing
22/03/22		180.66KB	Share
IXC Half Yearly Report and Accounts
22/02/22	PRICE SENSITIVE	1.02MB	Share
IXC Upcoming Presentations at 48th Annual NANOS Meeting
10/02/22		228.5KB	Share
IXC New Executive Director and Chairman Agreements
31/01/22	PRICE SENSITIVE	200.14KB	Share

REFRESH

1 2

(20min delay)
Last 8.0¢		Change 0.000(0.00%)		Mkt cap ! $6.012M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	28219	8.0¢

Sellers (Offers)

Price($)	Vol.	No.
8.6¢	2202	1

View Market Depth

No.	Vol.	Price($)
1	28219	0.080
1	6000	0.071
1	100000	0.070
1	32000	0.060
2	60001	0.047

Price($)	Vol.	No.
0.086	2202	1
0.089	82720	1
0.090	126146	1
0.095	100000	1
0.100	76646	2

Last trade - 10.05am 03/05/2024 (20 minute delay)

IXC (ASX) Chart

Day chart unavailable

INVEX THERAPEUTICS LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories